At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 13, 2026 at 08:01 ET
Rhythm Pharmaceuticals reported positive Phase 2 data for setmelanotide in Prader-Willi syndrome at ENDO 2026, showing clinically meaningful BMI reductions, fat mass loss with lean mass preservation, and improvements in hyperphagia and anxiety. The results de-risk the path to Phase 3 development in a large unmet-need population, reinforcing the MC4R agonism thesis.
- Phase 2 trial of setmelanotide in PWS (N=17) showed -3.06% mean BMI reduction at Month 6; 8 of 10 patients with moderate-to-severe hyperphagia achieved ≥7-point HQ-CT improvement.
- DEXA scans (N=16) showed +0.74% mean lean mass gain and -4.19% mean fat mass loss; 6 of 9 adults had >5% fat mass reduction.
- 10 of 15 patients with baseline PADQ >11 achieved ≥11-point improvement in anxiousness/distress behaviors.
- Safety profile consistent with established setmelanotide data; no new safety signals.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access